about
Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative DisordersGlia and alpha-synuclein in neurodegeneration: A complex interactionCurcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-SynucleinSignificance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease.Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progressionUrban air pollution: influences on olfactory function and pathology in exposed children and young adults.Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotectionTargeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure.A soluble α-synuclein construct forms a dynamic tetramer.The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.Versatile somatic gene transfer for modeling neurodegenerative diseases.Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systemsDysautonomia in Parkinson diseaseα-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controlsAlpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review.The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinson's Disease PatientsAggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neuronsCerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.Survival in synucleinopathies: A prospective cohort studyBent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease.Combination therapies: The next logical Step for the treatment of synucleinopathies?Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathyUbiquinone-quantum dot bioconjugates for in vitro and intracellular complex I sensing.Up-regulation of SNCA gene expression: implications to synucleinopathiesProdegenerative IκBα expression in oligodendroglial α-synuclein models of multiple system atrophy.Amyloidogenesis of natively unfolded proteins.Recent advances in biomedical applications of accelerator mass spectrometry.Multiple system atrophy: a primary oligodendrogliopathy.Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1AFine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy.Molecular pathology of Lewy body diseases.Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophyA spontaneous deletion of α-synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: effects on alcohol consumption.Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration.Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.Neuropathology underlying clinical variability in patients with synucleinopathies.Genetic variability in SNCA and Parkinson's disease.Examining the mechanisms that link β-amyloid and α-synuclein pathologies.
P2860
Q26779001-30F2254B-CAEE-47D8-BF20-E4DAC8BF374AQ26851153-8BC27A1F-D03F-44CB-B295-6B5C30F62655Q30410869-38438727-9036-42E0-8898-39BA9AF7231FQ30496676-CFC3ED8B-1DC0-48CF-94DB-1B5ED4F3CB76Q30501271-1AE973DF-6AC5-46BA-A562-4D9E14F30AA9Q33703977-29342541-3CDA-4850-AA0A-6F3C0143F2B9Q33916838-02CDC794-CBB3-4300-9044-BD5764D23346Q34032393-90D68011-6BF4-432E-BE4C-AAF98A0F4D4FQ34050129-C7A79E9F-96E7-4A1A-A759-81F19043F544Q34074501-C031F5B7-28D6-4768-9A15-DB50E975D667Q34285870-4D29B2E5-37ED-47DF-8703-0795F536E717Q34386339-9393EA48-918E-4249-81AC-BD76AC4B4A25Q34463831-05424446-3385-4311-BB9D-4A03CED8AC96Q34533573-1CC368DE-EA40-4FE0-AE9E-E6D95E4C941EQ35139572-12A30D9C-9C96-43C9-83B4-DE6A6658BE88Q35427654-9FB5611C-0B4D-4729-B5D4-C049605141E3Q35855302-7FE633B9-E405-4B11-8DA7-37A15CB730BEQ35863939-96E3412A-AFBC-42D9-8859-F5C3EF866598Q35986671-FBAAE5F1-986B-4522-8719-675787E28747Q36272234-ECC07E4B-3D02-4E69-90CB-1EC48507F750Q36373170-4A00E092-9FD0-462D-829A-DE583D9D0FADQ36563062-87B79152-AE45-4564-8F5C-2734BBE2CE69Q36672116-F9FCFCFA-FC97-4601-BE81-C12F39DE02C0Q36713295-88531A37-5B23-41BD-8A9F-E39DF7A91D0EQ37004246-1936E411-A438-48DC-9677-83AEFB361EF7Q37092530-DB47143E-6012-4F57-984F-993C762826DBQ37184755-DA81221E-EE3F-4ECA-BF88-B7A669526FE0Q37266360-37EC0006-D38A-432B-B539-311655428BACQ37282526-C149890F-4343-49AF-A2AD-85D01C528DF7Q37330540-8E8311B7-86F0-4019-8676-7313C4A4434EQ37432159-77940C4D-DF9C-430F-86EB-AB4B30DB6339Q37461525-D538BCAE-903F-4E23-970F-551B10D40408Q37462203-F9A35D42-CDBD-4D74-BB5C-5D8C7183120BQ37565960-D8733A5B-65B9-4774-984E-606E45494005Q37597181-7379B5ED-04C8-429C-BBF5-3621A9F5BB7EQ37873359-FB8CD6E6-1918-4B86-8C2B-393FCB2F176BQ37874476-99D6781D-BACA-4063-A96E-575A19D0BA54Q37896515-7EE04C05-D5F9-4BDB-86B2-870EEB31006DQ37907930-50ABCACF-315F-448B-A999-3631C3937E34Q38006559-71F309F7-0789-4A6A-A3EA-266BAAB90F1A
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Neuropathological spectrum of synucleinopathies.
@ast
Neuropathological spectrum of synucleinopathies.
@en
type
label
Neuropathological spectrum of synucleinopathies.
@ast
Neuropathological spectrum of synucleinopathies.
@en
prefLabel
Neuropathological spectrum of synucleinopathies.
@ast
Neuropathological spectrum of synucleinopathies.
@en
P356
P1433
P1476
Neuropathological spectrum of synucleinopathies.
@en
P2093
Kurt A Jellinger
P356
10.1002/MDS.10557
P407
P478
18 Suppl 6
P577
2003-09-01T00:00:00Z